Search Results - "Ikeda, Sachiya"

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice by Obata, Atsushi, Kubota, Naoto, Kubota, Tetsuya, Iwamoto, Masahiko, Sato, Hiroyuki, Sakurai, Yoshitaka, Takamoto, Iseki, Katsuyama, Hisayuki, Suzuki, Yoshiyuki, Fukazawa, Masanori, Ikeda, Sachiya, Iwayama, Kaito, Tokuyama, Kumpei, Ueki, Kohjiro, Kadowaki, Takashi

“…Sodium glucose cotransporter 2 inhibitors have attracted attention as they exert antidiabetic and antiobesity effects. In this study, we investigated the…”
Get full text

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice by Suzuki, Masayuki, Honda, Kiyofumi, Fukazawa, Masanori, Ozawa, Kazuharu, Hagita, Hitoshi, Kawai, Takahiro, Takeda, Minako, Yata, Tatsuo, Kawai, Mio, Fukuzawa, Taku, Kobayashi, Takamitsu, Sato, Tsutomu, Kawabe, Yoshiki, Ikeda, Sachiya

“…Sodium/glucose cotransporter 2 (SGLT2) is the predominant mediator of renal glucose reabsorption and is an emerging molecular target for the treatment of…”
Get more information

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects by Kasahara-Ito, Nahoko, Fukase, Hiroyuki, Ogama, Yoichiro, Saito, Tomohisa, Ohba, Yasuhiro, Shimada, Sumire, Takano, Yasuki, Ichihara, Tomoko, Terao, Kimio, Nakamichi, Noboru, Kumagai, Yuji, Ikeda, Sachiya

“…Tofogliflozin is a selective oral inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus. The pharmacokinetics,…”
Get more information

Pharmacokinetic and Pharmacodynamic Modeling of the Effect of an Sodium-Glucose Cotransporter Inhibitor, Phlorizin, on Renal Glucose Transport in Rats by YAMAGUCHI, Koji, KATO, Motohiro, SUZUKI, Masayuki, ASANUMA, Kimie, ASO, Yoshinori, IKEDA, Sachiya, ISHIGAI, Masaki

“…A pharmacokinetic and pharmacodynamic (PK-PD) model for the inhibitory effect of sodium-glucose cotransporter (SGLT) inhibitors on renal glucose reabsorption…”
Get full text

Discovery of Tofogliflozin, a Novel C‑Arylglucoside with an O‑Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes by Ohtake, Yoshihito, Sato, Tsutomu, Kobayashi, Takamitsu, Nishimoto, Masahiro, Taka, Naoki, Takano, Koji, Yamamoto, Keisuke, Ohmori, Masayuki, Yamaguchi, Marina, Takami, Kyoko, Yeu, Sang-Yong, Ahn, Koo-Hyeon, Matsuoka, Hiroharu, Morikawa, Kazumi, Suzuki, Masayuki, Hagita, Hitoshi, Ozawa, Kazuharu, Yamaguchi, Koji, Kato, Motohiro, Ikeda, Sachiya

“…Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes. In our efforts to discover…”
Get full text

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats by Nagata, Takumi, Fukazawa, Masanori, Honda, Kiyofumi, Yata, Tatsuo, Kawai, Mio, Yamane, Mizuki, Murao, Naoaki, Yamaguchi, Koji, Kato, Motohiro, Mitsui, Tetsuya, Suzuki, Yoshiyuki, Ikeda, Sachiya, Kawabe, Yoshiki

“…To understand the risk of hypoglycemia associated with urinary glucose excretion (UGE) induced by sodium-glucose cotransporter (SGLT) inhibitors, it is…”
Get more information

In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach by Yamaguchi, Koji, Kato, Motohiro, Suzuki, Masayuki, Hagita, Hitoshi, Takada, Maiko, Ayabe, Miho, Aso, Yoshinori, Ishigai, Masaki, Ikeda, Sachiya

“…To evaluate the relationship between the in vitro and in vivo potency of sodium-glucose cotransporter (SGLT) inhibitors, a pharmacokinetic and pharmacodynamic…”
Get more information

Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice by Yamaguchi, Koji, Kato, Motohiro, Ozawa, Kazuharu, Kawai, Takahiro, Yata, Tatsuo, Aso, Yoshinori, Ishigai, Masaki, Ikeda, Sachiya

“…The purpose of this study is to characterize the relationship between pharmacokinetics (PK) and pharmacodynamics (PD) of sodium-glucose cotransporter (SGLT)…”
Get more information

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP by Yamane, Mizuki, Kawashima, Kosuke, Yamaguchi, Koji, Nagao, Shunsuke, Sato, Mika, Suzuki, Masayuki, Honda, Kiyofumi, Hagita, Hitoshi, Kuhlmann, Olaf, Poirier, Agnes, Fowler, Stephen, Funk, Christoph, Simon, Sandrine, Aso, Yoshinori, Ikeda, Sachiya, Ishigai, Masaki

“…Abstract 1. The metabolism and drug-drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, were…”
Get full text

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes by Ohtake, Yoshihito, Sato, Tsutomu, Matsuoka, Hiroharu, Kobayashi, Takamitsu, Nishimoto, Masahiro, Taka, Naoki, Takano, Koji, Yamamoto, Keisuke, Ohmori, Masayuki, Higuchi, Takashi, Murakata, Masatoshi, Morikawa, Kazumi, Shimma, Nobuo, Suzuki, Masayuki, Hagita, Hitoshi, Ozawa, Kazuharu, Yamaguchi, Koji, Kato, Motohiro, Ikeda, Sachiya

“…C-Aryl 5a-carba-β-d-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the…”
Get full text

5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes by Ohtake, Yoshihito, Sato, Tsutomu, Matsuoka, Hiroharu, Nishimoto, Masahiro, Taka, Naoki, Takano, Koji, Yamamoto, Keisuke, Ohmori, Masayuki, Higuchi, Takashi, Murakata, Masatoshi, Kobayashi, Takamitsu, Morikawa, Kazumi, Shimma, Nobuo, Suzuki, Masayuki, Hagita, Hitoshi, Ozawa, Kazuharu, Yamaguchi, Koji, Kato, Motohiro, Ikeda, Sachiya

“…5a-Carba-β-d-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2 inhibition…”
Get full text

Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation by Tabira, Takeshi, Chui, De-Hua, Tanahashi, Hiroshi, Ozawa, Kazuharu, Ikeda, Sachiya, Checler, Frédéric, Ueda, Otoya, Suzuki, Hiroshi, Araki, Wataru, Inoue, Haruhisa, Shirotani, Keiro, Takahashi, Keikichi, Gallyas, Ferenc

“…Familial Alzheimer disease mutations of presenilin 1 (PS-1) enhance the generation of A beta1-42, indicating that PS-1 is involved in amyloidogenesis. However,…”
Get full text

C-Aryl 5a-carba-I2-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes by Ohtake, Yoshihito, Sato, Tsutomu, Matsuoka, Hiroharu, Kobayashi, Takamitsu, Nishimoto, Masahiro, Taka, Naoki, Takano, Koji, Yamamoto, Keisuke, Ohmori, Masayuki, Higuchi, Takashi, Murakata, Masatoshi, Morikawa, Kazumi, Shimma, Nobuo, Suzuki, Masayuki, Hagita, Hitoshi, Ozawa, Kazuharu, Yamaguchi, Koji, Kato, Motohiro, Ikeda, Sachiya

“…C-Aryl 5a-carba-I2-d-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the…”
Get full text

The Decrement of Muscarinic Receptor-Mediated Calcium Influx by Overexpression of APP in a Mouse Cholinergic Cell Line by KUNISHITA, TATSUHIDE, IKEDA, SACHIYA, ARAKI, WATARU, TABIRA, TAKESHI

“…KUNISHITA, T., IKEDA, S., ARAKI, W. and TABIRA, T. The Decrement of Muscarinic Receptor-Mediated Calcium Influx by Overexpression of APP in a Mouse Cholinergic…”
Get full text

5a-Carba-[beta]-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes by Ohtake, Yoshihito, Sato, Tsutomu, Matsuoka, Hiroharu, Nishimoto, Masahiro, Taka, Naoki, Takano, Koji, Yamamoto, Keisuke, Ohmori, Masayuki, Higuchi, Takashi, Murakata, Masatoshi, Kobayashi, Takamitsu, Morikawa, Kazumi, Shimma, Nobuo, Suzuki, Masayuki, Hagita, Hitoshi, Ozawa, Kazuharu, Yamaguchi, Koji, Kato, Motohiro, Ikeda, Sachiya

“…5a-Carba-[beta]-d-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2…”
Get full text

Oxidized low density lipoprotein caused CNS neuron cell death by Sugawa, Makoto, Ikeda, Sachiya, Kushima, Yoichi, Takashima, Yoshiaki, Cynshi, Osamu

“…Death induced by oxidized low density lipoproteins (oxLDL) to embryonic CNS neuronal and neuroblastoma cells was investigated. Cell damage and viability were…”
Get full text

Secretion kinetics of Alzheimer's amyloid beta-protein differs from secreted beta-amyloid precursor protein by Araki, W, Kunishita, T, Takahashi, K, Ikeda, S, Tabira, T

“…Amyloid beta-protein (A beta) and secreted beta-amyloid precursor protein (sAPP), derived from beta-amyloid precursor protein (APP), are normally released by…”
Get full text

Demonstration of amyloid beta-protein secretion in a mouse neuronal cell line by Araki, W, Kunishita, T, Takahashi, K, Ikeda, S, Tabira, T

“…We investigated the secretion of amyloid beta-protein (beta AP) in a mouse neuronal cell line SN49. SN49 cells stably transfected with mouse beta-amyloid…”
Get more information

Polyclonal Antibodies to DNA Modified with 4‐Nitroquinoline 1‐Oxide: Application for the Detection of 4‐Nitroquinoline 1‐Oxide‐DNA Adducts in vivo by Morita, Toshiteru, Ikeda, Sachiya, Minoura, Yasushi, Kojima, Misaki, Tada, Mariko

“…Antibodies against 4‐nitroquinoline 1‐oxide (4NQO) adducts were elicited in rabbits immunized with 4NQO‐modified DNA complexed with methylated bovine serum…”
Get full text